SKINHEALTH SYSTEMS INC (SKIN)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
$10.35-6.33%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-11-04
QuarterlyIQ Insights · SKIN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 18.2% |
| Our one-year growth estimate | diamond | 1.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 16.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 1 industry peers
SKIN — capital allocation
Dated 2026-10-14
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Why it matters: Revenue has been uneven, and the growth priority is behind. A year-over-year increase would show the top line is gaining ground.
Supportive ifOn Nov. 5, reported revenue is higher year over year and above the prior quarter’s $64.9 million.
Worry ifOn Nov. 5, reported revenue is lower year over year or below $64.9 million.
Why it matters: Operating income turned positive in 2026-Q2 as losses narrowed. Staying above zero would show that progress continues.
Supportive ifThe Nov. 5 report shows operating income above zero and net loss below $2.67 million.
Worry ifThe Nov. 5 report shows operating income below zero or net loss above $2.67 million.
Why it matters: SKIN repaid its 1.25% notes due 2026 in full. The next report can show how cash levels changed after that payment.
Watch forThe Nov. 5 report shows cash and cash equivalents above the prior quarter’s level after the note repayment.
Also watch forThe Nov. 5 report shows cash and cash equivalents below the prior quarter’s level after the note repayment.
Why it matters: The 1-for-20 split was meant to help SKIN meet Nasdaq’s minimum bid-price rule. A Nasdaq notice would confirm the split worked for this goal.
Supportive ifNasdaq tells SKIN in writing that it now meets the $1 minimum bid-price rule.
Worry ifNasdaq says SKIN still does not meet the rule, or the company reports another bid-price notice.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$291 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $908 loss on $10,000 · 9.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,874 loss on $10,000 · 68.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The split may not keep the share price above Nasdaq’s $1 line. A lasting drop could put listing compliance back at risk.
Worry ifSKIN’s split-adjusted share price falls below $1 and stays there through a Nasdaq compliance review.
Less concerning ifSKIN stays above $1 through the review, and Nasdaq confirms compliance.